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We have identified a new immunoglobulin heavy-chain enhancer element, designated x, between the LE2
and ,E3 elements. The -w enhancer element is transcriptionally active primarily during early stages of B-cell
development but becomes virtually inactive during B-cell maturation at about the stage of immunoglobulin K
light-chain gene rearrangement. Mutational analysis suggests that the wr element is crucial for immunoglobulin
heavy-chain enhancer activity at the pre-B-cell stage but is almost irrelevant for enhancer activity at the mature
B-cell or plasma-cell stage. The activity ofthew enhancer element correlates with the presence of an apparently
pre-B-cell-specific protein-DNA complex. The similarity of the wr site to recognition sequences for members of
the ets gene family suggests that the protein(s) interacting with the w site most likely are as-related
transcription factors.
The intronic immunoglobulin heavy-chain (IgH) enhancer
is located between the last joining-region exon (J,) and the
first constant-region exon (C,J) (8, 21). This enhancer has
been shown to be of utmost importance for both B-cell-
specific and developmental-stage-specific expression of the
IgH gene as well as for the recombinational process (17, 42).
Additional enhancers 3' of the IgH gene have been identified
but have not been characterized in more detail (13, 45).
A 700-bp XbaI-EcoRI fragment (±700) contains most of
the activity of the intronic IgH enhancer and functions
during all stages of B-cell development but is inactive in
nonlymphoid cells (39). The IgH enhancer shows a complex
modular arrangement of several different overlapping stim-
ulatory and negative elements (see Fig. 1) (21, 39, 42). The
B-cell specificity of the IgH enhancer is apparently regulated
by positively acting B-cell-specific enhancer elements, includ-
ing octamer and 3B, negatively acting non-B-cell-specific
silencer elements, and protein-protein interactions between
these B-cell-specific factors and ubiquitously expressed tran-
scription factors (4, 5, 11, 20, 31, 33, 39, 42, 44, 52, 55, 65, 73).
We have characterized the B-cell-specific enhancer ele-
ment, ,uB, in more detail and have shown that the pB
element is a critical component of the IgH enhancer in
lymphoid cell-specific expression (44, 52). Both the octamer
and the pB elements are active during all stages of B-cell
development, correlating with the transcriptional activity of
IgH genes (39, 44, 52), even though the octamer element
appears to be less active at the pre-B-cell stage.
We now report the identification of a novel enhancer
element, designated Tr, between the ,E2 and ,uE3 elements
of the IgH enhancer (see Fig. 1). We show that this highly
conserved enhancer element is pre-B-cell specific and of
crucial importance for the activity of the IgH enhancer at the
pre-B-cell stage only. The similarity of the Tr site to binding
sites for members of the ets gene family suggests that the
protein(s) interacting with the 7r site belong to the ets gene
family.
* Corresponding author.
MATERIALS AND METHODS
Cell cultures. The following cells were grown as described
previously (2, 3, 30, 41, 43, 51, 56): S194 (murine myeloma),
NIH 3T3 (murine fibroblasts), HeLa (human cervical carci-
noma), U-343 Mg (human glioma), U-251 Mg Ag Cll (human
glioma), C127 (murine mammary cells), L929 (murine fibro-
blasts), U-706T (human glioma), U-Cl 2:6 (human glioma),
U-1240 Mg (human glioma), P19 (murine teratocarcinoma),
EJ (human bladder carcinoma), U-937 (human monocytic
cells), Jurkat (mature human T-cell line), PD31 (Abelson
murine leukemia virus-transformed pre-B-cell line), 230-238
(murine pre-B-cell line), 38B9 (murine pre-B-cell line),
K40B.1 (murine pre-B-cell line), K40B.2 (murine pre-B-cell
line), NFS5.3 (murine late pre-B-cell line), 70Z/3 (murine
late pre-B-cell line), BASC 6C2 (murine pre-B-cell line),
WEHI 231 (murine mature B-cell line), X63 Ag8 (murine
myeloma), Namalwa (human mature B-cell line), MOLT 3
(mature human T-cell line), MOLT 4 (mature human T-cell
line), HAFIL (murine Harvey v-ras-transformed early pre-
B-cell line), and 32D (murine early myeloid cell line).
Nuclear extracts. Nuclear extracts were prepared by the
method of Dignam et al. (14). All buffers included leupeptin
at 0.3 p,g/ml, 5 mM phenylmethylsulfonyl fluoride (PMSF),
antipain at 0.3 p1g/ml, and aprotinin at 2 p,g/ml.
DNase I footprinting analysis. p700 WT/A56 and ,u700
Tr-/A56 (see Fig. 1 and 6 and Results) were digested with
HindIII and BamHI; the restriction sites were located 5' and
3' of the enhancer in the A56 plasmid, respectively (22, 39).
The 700-bp IgH enhancer fragments were gel purified, di-
gested with Hinfl, dephosphorylated, and end labeled with
[y-32P]ATP and T4 polynucleotide kinase at the 5' end of the
noncoding strand. After digestion with DdeI, end-labeled
Hinff-DdeI fragments were gel purified. DNase I footprint-
ing was performed as described by Jones et al. (32) with 0.3
to 0.8 ng of end-labeled IgH enhancer fragments (8,000 cpm),
20 ,ug of total nuclear extract or no protein, 1 pg of
poly(dI-dC) (Pharmacia), and 2% polyvinyl alcohol in a 50-lu
volume. A G+A Maxam-Gilbert (50) sequencing reaction of
the end-labeled IgH enhancer fragments was run as a
marker.
EMSA. DNA-binding reactions and electrophoretic mobil-
ity shift assays (EMSA) were performed as described previ-
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FIG. 1. Schematic diagram of regulatory regions in the murine IgH enhancer and location of the wr enhancer element. (a) IgH gene
structure. The transcription initiation site is indicated by the arrow. The leader (L)-, variable (V)-, diversity (D)-, joining (J)-, and constant
(C)-region exons are shown as hatched boxes. Promoter regions are in black. Enhancers are indicated by shaded areas in the introns. S
indicates a switch region in the IgH gene. (b) Schematic diagram of regulatory regions in the murine IgH enhancer and location of the rr
enhancer element. Filled symbols represent the various transcription factor-binding sites as indicated below the diagram and described in the
text. Open boxes represent exons for the constant and variable regions, and the line indicates the intron. The sequence of 'rr is indicated by
the expansion below the diagram. The enhancer fragment referred to as 7°000 extends between the XbaI and EcoRI sites. ,300 extends
between the PvuII and EcoRI sites. (c) Sequence of the rr site and flanking nucleotides used for oligonucleotide constructs. The box indicates
the sequence of the ir site. Boldface nucleotides were derived from the IgH enhancer sequence. Italic nucleotides flank the oligonucleotide
to create a restriction site.
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FIG. 2. The vr site acts as a strong enhancer element in BASC
6C2 pre-B cells. Shown are the CAT activities of iT oligonucleotide
constructs, the enhancerless A56 background plasmid (A56), and the
SV40 enhancer (pSV) in BASC 6C2 pre-B cells. Ac-Chl, acetylated
chloramphenicol; Chl, nonacetylated chloramphenicol.
ously (6, 7). Samples of 20 pl containing 5 p,g of nuclear
extract, 0.5 ,ug of heparin-agarose-purified nuclear factors,
or 4 RI of affinity-purified nuclear factor ir were incubated
with 0.1 to 0.2 ng of a 32P-labeled immunoglobulin (Ig) vr
wild-type DNA fragment (5,000 cpm)-10 mM Tris-Cl (pH
7.5)-50 mM NaCl-1 mM dithiothreitol (DlT)-1 mM EDTA-
1.75% polyvinyl alcohol-5% glycerol-2 ,ug of bovine serum
albumin (Boehringer) and with 2 ,ug of poly(dI-dC), 1 F±g of
poly(dI-dC), or 0.4 pug of poly(dI-dC) for total nuclear
extract, heparin-agarose-purified nuclear factors, or affinity-
purified nuclear factors, respectively. Samples were incu-
bated in the presence or absence of competitor oligonucleo-
tides for 15 min at room temperature and run on 4%
polyacrylamide gels containing as a buffer 25 mM Tris-HCl
(pH 8.5), 190 mM glycine, and 1 mM EDTA.
Oligonucleotides used for competition studies were as
follows:
(i) Ig rr wild-type oligonucleotide
5'-TCGACTGGCAGGAAGCAGGTCATGC-3'
3'-GACCGTOCTTOGTCCAGTAOGAGCT-5'
(ii) Ig r Ml oligonucleotide
5'-TCGACTGGCATTAAGCAGGTCATGC-3'
3'-GACCGTAATTCGTCCAGTACGAGCT-5'
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FIG. 3. The Tr enhancer element is active only in pre-B cells. Shown are the relative CAT activities of -rr (ir-CAT) and p.B (pLB)
oligonucleotide constructs, the IgH enhancer (pL300), and the SV40 enhancer (pSV) in B cells of different developmental stages. The CAT
activity of each construct transfected into S194 myeloma, WEHI 231 mature B, HAFrL early pre-B, or PD31 pre-B cells is compared with
that of the enhancerless A56 background plasmid. p300 extends between the PvuII and EcoRI sites (Fig. 1) (39). CAT values are averages
derived from one representative experiment involving two independent transfections. Repeated experiments produced similar results, with
standard deviations of less than 15% compared with the values given.
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FIG. 4. Relative CAT activity of the ir oligonucleotide trimer in different cell types. Shown is the relative CAT activity of a vr
oligonucleotide trimer construct in B cells of different developmental stages and non-B cells. The CAT activity of each construct transfected
into S194 or X63 Ag8 myeloma, WEHI 231 mature B, NFS5.3 late pre-B, HAFTL early pre-B, PD31, BASC 6C2, or 230-238 pre-B, Jurkat
mature T, U-937 monocytic, or C127 mammary cells is compared with that of the enhancerless A56 background plasmid. CAT values are
averages derived from two representative experiments involving two independent transfections. Repeated experiments produced similar
results, with standard deviations of less than 20% compared with the values given.
(iii) Ig rr M2 oligonucleotide
5'-TCGACTGGCAGGAAGCCTTTCATGC-3'
3'-GACCGTCCTTCGGAAAGTACGAGCT-5'
(iv) Ig rr M3 oligonucleotide
5'-TCGACTGGCAGGAAGCAGGTTTTGOC-3'
3'-GACCGTCCTTCOGTCCAAAACGAGCT-5'
(v) JC virus enhancer (18) oligonucleotide
5'-TCGACATGCTTGGCTGGCAAGCCATCC-3'
3'-GTACGAACCGACCGTTCGGTAGGAGCT-5'
Chromatographic purification. Heparin-agarose (0.5 ml)
was equilibrated with buffer D (20mM N-2-hydroxyethylpip-
erazine-N'-2-ethanesulfonic acid [HEPES] [pH 7.9], 0.2mM
EDTA, 0.5 mM DTT, 0.1 M KCI, 20% glycerol). Nuclear
extract (10 mg) in buffer D was applied five times to a
heparin-agarose column and washed with 10 column vol-
umes of buffer D. Nuclear proteins were step eluted from the
heparin-agarose column with 2.5 column volumes of buffer D
containing, successively, 150, 250, 350, 500, and 900 mM
KCI and dialyzed against buffer D. Activity was measured
by EMSA and eluted primarily in the 250 and 350 mM KCI
fractions.
DNA affinity chromatography was performed as described
by Kadonaga and Tjian (34) with a double-stranded 25-bp ir
oligonucleotide
5'-TCGACTGGCAGGAAGCAGGTCATGC-3'
3'-GACCGTCCTTCOGTCCAGTACGAGCT-5'
from the IgH enhancer with TCGA 5'-overhanging ends.
Chromatography was carried out with buffer F (20 mM
KH2PO4 [pH 7.2], 0.1 M KCI, 1 mM EDTA, 1 mM DTT,
10% glycerol, 1 mM PMSF). The sample was mixed with 20
,g of poly(dI-dC) per ml on ice for 30 min, mixed with the
affinity matrix for 1 h at 4°C, and loaded into a column. The
column was washed with five column volumes of buffer F
and step eluted with buffer F containing, successively, 200,
300, 500, and 1,000 mM KCI. Activity as measured by
EMSA eluted primarily in the 200 and 300 mM fractions.
Constructs and mutants. For enhancer-chloramphenicol
acetyltransferase (CAT) plasmid construction, the XhoI-
linked 700-bp IgH enhancer was inserted into the SalI site
of the A56-c-fos-CAT plasmid in the B orientation (see Fig.
lb and 6) as previously described by Gilman et al. (22)
and Lenardo et al. (39). A synthetic 25-bp rr oligonucleo-
tide
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FIG. 5. Relative CAT activities of ir oligonucleotide mutants. (a) Schematic diagram of the IgH enhancer regulatory elements. (b)
Sequence of the rr site and flanking regions. (c) Sequences of wild-type and mutant rr oligonucleotides and CAT assay results obtained in PD31
pre-B cells. CAT values are averages derived from one representative experiment involving two independent transfections. Repeated
experiments produced similar results, with standard deviations of less than 20% compared with the values given. Boldface nucleotides are
derived from the IgH enhancer sequence. Lightface nucleotides indicate flanking sequences creating a restriction site for insertion into
plasmids. Underlined sequences indicate nucleotides introduced by mutations.
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5'-TCGACTGGCAGGAAGCAGGTCATGC-3'
3'-GACCGTCCTTCGTCCAGTACGAGCT-5'
containing Sall and XhoI ends was inserted as a monomer, a
trimer, and a nonamer into the SalI site of the A56-c-fos-
CAT plasmid (22, 39). Similarly, trimers of mutant oligonu-
cleotides Ig ir Ml, Ig ur M2, and Ig r M3 (see above) were
inserted into the SalI site in the A56-c-fos-CAT plasmid.
Site-directed mutagenesis. Specific site-directed mutagen-
esis of four nucleotides in the ir DNA motif of the murine
IgH enhancer were introduced by the gap-heteroduplex
method (66) with oligonucleotide 5'-CTGCAGCAGCTGG
CCTCGAGCAGGTCATGTGG-3' (see Fig. 6b). Mutant IgH
enhancer constructs were partially sequenced. At least two
independent isolates of each mutant construct were grown,
analyzed, and used for the experiments.
DNA transfection assays. Cells were transfected with 10 ,ug
of DNA by the DEAE-dextran method (39, 56), except that
C127 cells were transfected by the calcium phosphate copre-
cipitation method (39, 57). The cells were harvested 48 h
after transfection, and 30 to 100 ,ug of heat-inactivated (39)
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'FIG. 6. Mutation of the 7r site affects 700-bp IgH enhancer
mys4oma transcriptional activity only in pre-B cells. (a) Relative CAT activ-
ities of ,u700 WT and ,u700 rr- IgH enhancers in B cells of different
developmental stages. CAT values are averages derived from two
representative experiments involving two independent transfec-
tions. Repeated experiments produced similar results, with standard
C, deviations of less than 10% compared with the values given. (b)
Regulatory elements in the IgH enhancer. The wild-type sequence
of rr is indicated by the expansion above the diagram. Arrows point
pE4 OCTA IN2 to the nucleotides introduced by mutations into the wild-type
sequence.
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MUTANT 3 (M3) TCGACTGGCAGGAAGCAGGTTTTGC 118
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cell extract was assayed for CAT activity as described
previously (24) in a 1- or 2-h incubation at 37°C. Transfec-
tions for every construct were performed independently in
duplicate and repeated two to four times. Samples were
analyzed by thin-layer chromatography (24). The percentage
of acetylated chloramphenicol was determined by cutting
out samples of nonacetylated and acetylated forms of chlor-
amphenicol and measuring the amount of radioactivity by
liquid scintillation counting.
RESULTS
Identification of a novel enhancer element, w, in the IgH
enhancer. While analyzing the murine IgH enhancer by
DNase footprinting for protein-DNA interactions, we re-
cently (44) observed between the pLE2 and ,uE3 enhancer
elements a putative lymphoid cell-specific footprint that had
not been previously described (Fig. 1). The sequence of this
putative enhancer element, 5'-CAGGAAGCAGGT-3', is de-
picted in Fig. lb, and we refer to this site as the ir site.
To determine whether the site indeed acts as an en-
hancer element, we generated a synthetic 25-bp oligonucle-
otide containing the ir DNA motif (Fig. 1) (see Materials and
Methods). We inserted one, three, or nine copies of this
oligonucleotide upstream of the truncated c-fos promoter in
the A56 plasmid (22). Enhancer activity was measured as the
ability of the different constructs to induce transcription of
the CAT gene after transient expression in the murine
pre-B-cell line BASC 6C2 (30, 56). The transcriptional activ-
NF-Tdcl
5'-TGGCAGGAAGCAGGTCA-3'
3'-ACCGTgCTTCGTCCAGT-51
S.es S* 0
H
r-*0
5'-TGGCCTCGAGCAGGTCA-3'
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.0 a 5
FIG. 7. Binding of nuclear factors to wild-type and mutant vr
sites in the IgH enhancer. (A and B) DNase I footprinting assays
with wild-type (A) and mutant (B) noncoding strands of the IgH
enhancer fragment. Labeled enhancer fragments were incubated
with 20 ,ug of total nuclear extract from HAFTL pre-B cells (lane 3).
Lane 2 was a control reaction without protein. A G+A Maxam-
Gilbert sequencing reaction of the same DNA fragments was run as
a marker (lane 1). The positions and names of enhancer elements in
the IgH enhancer are indicated by boxes together with the coordi-
nates of each site as described by Ephrussi et al. (15). The open box
in panel B indicates the position of the altered rr site. (C) Summary
of apparent interactions at the r site. The DNA sequences contain-
ing the wild-type or mutant Ir site are shown. Hypersensitive sites,
seen in DNase I footprinting assays, are indicated by an arrow and
an H. Nucleotides protected in the DNase I footprinting assays are
indicated by solid circles. Minimal binding sites for protein-DNA
complexes 1 and 3, based on the results of these DNase I footprint-
ing assays and EMSA (see Fig. 11 and 12), are indicated above the
DNA sequences. The putative binding site for pre-B-cell-specific
activity is indicated by the shaded box.
ities of these constructs were compared with that of the
parental enhancerless A56 plasmid itself. pSV2CAT, which
contains the simian virus 40 (SV40) enhancer (24), served as
a positive control and was very active in BASC 6C2 cells. As
shown in Fig. 2, very little CAT activity was detectable with
the A56 plasmid itself, whereas one copy of the rr element
stimulated transcription almost 10-fold. Enhancer activity
increased with increased copy number, such that nine copies
of the Fr element stimulated transcription by more than
400-fold. These results indicate that the r site is a very
powerful enhancing element.
The wr enhancer element is active only in pre-B cells. To
determine whether the r enhancer element is regulated
during B-cell development, we transfected murine cell lines
representing different stages of B-cell development with the
A56 plasmid containing one, three, or nine copies of the
enhancer element or containing three copies of another,
lymphoid cell-specific IgH enhancer element, ,B (44).
pSV2CAT, ,u300 (the region between the PvuII and EcoRI
sites shown in Fig. 1), and R700 (the region between the
XbaI and EcoRI sites shown in Fig. 1) (39) served as positive
controls. The SV40 enhancer and IgH enhancer fragments
,u300 and ,u700 (data not shown) stimulated transcription in
all cell lines. However, the 'rr enhancer element was active
only in pre-B-cell lines HAFTL, PD31, and BASC 6C2 and
virtually inactive in mature B-cell line WEHI 231 or my-
eloma cell line S194 (Fig. 3). Only with nine copies of the rr
enhancer element was some activity detected in the my-
eloma cell line, but no activity was seen in the mature B-cell
line. Three copies of the ,uB enhancer, in contrast, did not
express any intrinsic enhancer activity in any cell line.
To test in more detail the stage and tissue specificity of the
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FIG. 8. Binding of nuclear factors from various cell types to the
'r site in the IgH enhancer. Shown is a DNase I footprinting assay
done with the noncoding strand of the IgH enhancer fragment. The
labeled enhancer fragment was incubated with 20 p.g of total nuclear
extract from L929 (murine fibroblastic), C127 (murine mammary),
EJ (human bladder carcinoma), U-Cl 2:6 (human glioma), S194
(murine myeloma), WEHI 231 (murine mature B), NFS5.3 (murine
late pre-B), PD31 (murine pre-B), BASC 6C2 (murine pre-B),
HAFrL (murine early pre-B), Jurkat (mature human T), 32D
(murine early myeloid), and U-937 (human monocytic) cells as
indicated above the lanes. Lanes 2 and 16 were control reactions
without protein. A G+A Maxam-Gilbert sequencing reaction of the
same DNA fragments was run as a marker (lane 1). The positions
and names of enhancer elements in the IgH enhancer are indicated
by boxes together with the coordinates of each site as described by
Ephrussi et al. (15).
'Fr enhancer element, we transfected a wider range of cell
lines with the A56 plasmid containing three copies of the 'r
enhancer element and compared its activity in these cell
lines with that of the parental A56 plasmid. Again, the
enhancer element was a potent enhancer only in pre-B-cell
lines, increasing transcription 14- to 36-fold, depending on
the cell line (Fig. 4). Practically no enhancer activity was
detected in late pre-B, mature B, or myeloma cells. Further-
more, the Tr enhancer element was also inactive in Jurkat T
cells, U-937 monocytic cells, and C127 mammary cells.
These results suggest that the IgH enhancer contains in
addition to the lymphoid cell-specific enhancer elements ,uB
and octamer, which are active during all stages of B-cell
development, a stage-specific enhancer element, Tr.
Effect of mutations on the activity of an isolated 'rr enhancer
element. To further define the sequence requirements for 'r
enhancer activity, we synthesized several oligonucleotides
(Ml, M2, and M3) that spanned the rr element and that
contained mutations of either two or three nucleotides in the
'rr site (Fig. 5). Three copies of these mutant oligonucleotides
were inserted into the A56 plasmid. The transcriptional
activities of mutant 'r enhancers were compared with those
of the wild-type 'r enhancer trimer and the parental A56
plasmid (Fig. 5). The mutation in Ml, in the 5' half of the vr
site, almost completely abrogated all enhancer activity (Fig.
5). The mutation in M2 reduced the enhancer activity of the
zr element only slightly, and the mutation in M3, at the 3' end
of the r site, had no effect on transcriptional activity (Fig. 5).
These data suggest that the 5' half of the 7r site contains
most, if not all, of the sequence required for enhancer
activity.
Mutation of the 'rr site reduces the activity of the IgH
enhancer specifically in pre-B cells. To test whether the rr
enhancer element contributes to the activity of the IgH
enhancer in the context of the whole 700-bp enhancer, we
introduced a mutation affecting the same region of 'r as the
Ml mutation, which inhibits the function of an isolated rr
element, into the rr site of p700 (Fig. 6b). The full-length
700-bp wild-type (,700 WT) and mutant (,u00 '-) IgH
enhancers, cloned into the A56 plasmid (22), were transiently
expressed in B-cell lines of different developmental stages,
and the transcriptional activity of the mutant enhancer was
compared with that of the wild-type enhancer. Mutation
of the rr site within R700 drastically reduced the activity
of the IgH enhancer in the pre-B-cell lines HAFTL and
PD31 (Fig. 6a) but had only a slight effect in the mature
B-cell line WEHI 231 or in the myeloma cell lines S194
and X63 Ag8. CAT activity was reduced by -65% in PD31
and by more than 80% in HAFTL pre-B cells but at most
20% in mature B or myeloma cells (Fig. 6a). These data most
vividly illustrate the pre-B-cell specificity of the 'r enhancer
element and strongly suggest that the 'r site is an important
element for transcriptional control of the IgH enhancer at the
pre-B-cell stage but not during later stages of B-cell devel-
opment.
Mutation of the Tr site inhibits the binding of a nuclear
factor to the IgH enhancer. To correlate the functional data
described above with the binding of a specific protein to the
'rr site and to confirm that mutation of the 'r site decreases the
binding of a specific nuclear factor, we carried out DNase I
footprinting experiments with the noncoding strand of the
,u700 WT or ,u00 'r- IgH enhancer. We compared a
Hinfl-DdeI fragment of p700 WT with that of ,700 ir- by
using a nuclear extract derived from the pre-B-cell line
HAFFL. Proteins bound to ,uE2, p,E3, ,uE5, and ,uB were
detected in both wild-type and mutant enhancers (Fig. 7A
and B). The HAFTL extract gave rise to a strong footprint
over the wild-type ir site (Fig. 7A and C). In contrast, no
footprint was seen over the functionally important 5' half of
the mutant Tr site (Fig. 7B and C). Interestingly, a footprint
over the functionally inactive 3' half of the mutant Fr site was
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FIG. 9. A variety of nuclear factors interact with the IgH rr site. Shown is an EMSA performed with synthetic oligonucleotides coding for
the Tr site. Labeled Tr oligonucleotides were incubated with 5 ,ug of nuclear extract from HeLa (human cervical carcinoma), U-251 Mg Ag Cll,
U-343 Mg, and U-706T (human glioma), C127 (murine mammary), EJ (human bladder carcinoma), U-937 (human monocytic), 32D (murine
early myeloid), P19 (murine teratocarcinoma), Jurkat, MOLT 3, and MOLT 4 (mature human T), NFS5.3 and 70Z/3 (murine late pre-B),
WEHI 231 (murine mature B), HAFTL (murine early pre-B), 38B9, BASC 6C2, PD31, K40B.1, K40B.2, and 230-238 (murine pre-B),
Namalwa (human mature B), and S194 (murine myeloma) cells as indicated above the lanes. The arrowhead indicates the putative
pre-B-cell-specific factor NF-'Tr; the numbers indicate the different DNA-protein complexes.
still present (Fig. 7B), suggesting the presence of two sepa-
rate binding sites for two different factors in the 7r site (Fig.
7C). Similar results were obtained with the coding strand
(data not shown). Apparent protein-DNA interactions over
the Tr site, based on the results of these DNase I footprinting
assays and EMSA (see Fig. 11 and 12) are shown in Fig. 7C.
Our results confirm that mutation of the Tr site indeed
decreases the affinity for a specific Tr-binding factor and also
X Hep.-
Seph wr-Seph.
oO° s 0g01mM\
z cm Ln 0 0 I;I C\J rql) C\i to LO\KC
suggest the binding of at least two factors to different regions
of the -rr site.
To determine whether a pre-B-cell-specific protein binds
to the r site, we performed DNase I footprinting experi-
ments with the noncoding (Fig. 8) and coding (data not
shown) strands of the ,u700 IgH enhancer. We compared
nuclear extracts derived from several different cell types of
both lymphoid and nonlymphoid origins. Proteins bound to
,uE1, ,uE2, ,uE3, and E were detected in extracts of most cell
types (Fig. 8). A strong footprint over the ,uB DNA motif
was seen in extracts from B and T cells, as well as myeloid
cells, but was absent in extracts from nonhematopoietic
glioma, fibroblastic, bladder carcinoma, and mammary cells
(Fig. 8). Protein-DNA interactions over the r site appeared
to be more complex. A footprint over the ir DNA motif was
detected in every nuclear extract (Fig. 8) that had a promi-
nent hypersensitive site at the 5' end of the ir site. Extracts
from B and T cells, as well as from myeloid cells, gave rise
to a footprint that extended over the full Tr site, whereas a
4-
3-
2-
3 -
1 2 3 4 5 b
FIG. 10. DNA affinity purification of ir-binding proteins. Shown
is an EMSA performed with synthetic oligonucleotides coding for
the rr site. Labeled mT oligonucleotides were incubated with equiva-
lent amounts of total nuclear extract or heparin-Sepharose (Hep.-
Seph.)-purified or rr oligonucleotide-Sepharose (irr-Seph.) affinity-
purified nuclear proteins eluted at different KCI salt concentrations.
A total nuclear extract from HAFTL cells was first purified over
heparin-Sepharose, and the 350 mM KCI eluate was further purified
over Tr oligonucleotide-Sepharose. The arrowhead indicates the
pre-B-cell-specific factor NF-'r; the numbers indicate the different
DNA-protein complexes.
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FIG. 11. A pre-B-cell-specific nuclear protein, NF-ir, binds to
the IgH 'f site. Shown is an EMSA performed with synthetic
oligonucleotides coding for the ir site. Labeled vr oligonucleotides
were incubated with 1 p1g of heparin-Sepharose-purified nuclear
extract from HeLa (human cervical carcinoma), U-1240 Mg (human
glioma), BASC 6C2 (murine pre-B), WEHI 231 (murine mature B),
and HAFIL (murine early pre-B) cells as indicated above the lanes.
The arrowhead indicates the pre-B-cell-specific factor NF-ir; the
numbers indicate the different DNA-protein complexes.
second hypersensitive site was induced in the middle of the
'v site by extracts from nonhematopoietic cells. However, no
difference was revealed between footprints caused by ex-
tracts from B cells of different developmental stages, sug-
gesting a more subtle difference between the '-binding
factors in pre-B cells and mature B or myeloma cells.
B-cell- and pre-B-cell-specific proteins bind to the en-
hancer element. To determine the tissue specificity of the
site and to characterize in more detail the proteins that
interact specifically with the enhancer element, we per-
formed EMSA with a ir oligonucleotide as a probe. We
compared the abilities of nuclear extracts from a variety of
different cell types to form complexes with the r DNA motif.
The 'r oligonucleotide formed several complexes with nu-
clear proteins present in extracts from different cell types
(Fig. 9). We could distinguish at least 11 different complexes,
some of them showing a strikingly tissue-specific expression
pattern. Complex 3 was observed only in B cells, whereas
complex 10 was only formed by extracts from nonhe-
matopoietic cells. Complex 7 was observed only in pre-B-
cell line BASC 6C2. Interestingly, complex 3 was not
present in nuclear extracts from S194 myeloma cells but was
present in extracts from both pre-B and mature B cells.
Complex 2 was also present in extracts from both pre-B and
mature B cells. Complex 1 was very weak but appeared to be
present mainly in pre-B cells and probably in T cells.
Overall, the complexity of the electrophoretic mobility shift
pattern did not enable us to determine which protein-DNA
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FIG. 12. Point mutation Ml but not M2 or M3 abolishes the
binding of NF-'rr to the rr site. Shown is an EMSA performed with
synthetic oligonucleotides coding for the rr site. Assays with affin-
ity-purified nuclear proteins from HAFIL cells were carried out
with no competitor (lane 1), with 10, 100, or 300 ng of the wild-type
'rr oligonucleotide (lanes 2 to 4) or the mutant Ir oligonucleotide Ml
(lanes 5 to 7), M2 (lanes 8 to 10), or M3 (lanes 11 to 13), or with a
nonspecific JC virus enhancer oligonucleotide (lanes 14 and 15).
complex might be relevant for the activity of the r site and,
like the DNase I footprinting experiments, these experi-
ments suggested that nuclear extracts from a variety of
different cell types contain proteins that have similar or
identical binding specificities for the vr site in vitro.
To characterize further the proteins interacting with the 'r
enhancer element, we fractionated nuclear extracts over
heparin-Sepharose (Fig. 10). We performed EMSA with
heparin-Sepharose-purified nuclear proteins from pre-B-cell
lines BASC 6C2 and HAFTL, mature B-cell line WEHI 231,
glioma cell line U-1240 Mg, and cervical carcinoma cell line
HeLa (Fig. 11). As shown in Fig. 11, complex 1 appeared to
be present in extracts from the two pre-B-cell lines but not in
extracts from mature B, glioma, or cervical carcinoma cells.
We refer to complex 1 as NF-mr. Complexes 2 and 3 were
present in both pre-B and mature B cells but not in glioma or
cervical carcinoma cells. Complexes 10 and 11 were formed
only by proteins present in glioma and cervical carcinoma
cells.
These results indicate that a variety of different tissue-
restricted proteins interact with the Fr enhancer element. The
data also suggest that NF-r may be a pre-B-cell-specific
nuclear factor that correlates with the pre-B-cell-specific
activity of the ir enhancer element, although additional
experiments will be needed to prove this suggestion.
Further purification of ir-binding factors was achieved by
affinity chromatography of a heparin-Sepharose-fractionated
nuclear extract from the pre-B-cell line HAFTL over a 'r
oligonucleotide-Sepharose column. Complexes 1 to 4 were
the major proteins eluting from the ir-Sepharose column
(Fig. 10). Complexes 1 and 2 were the major components of
the 200 and 300 mM KCl eluates.
Mutations affecting the activity of the ii enhancer element
inhibit the binding of pre-B-cell-specific nuclear factor NF-Wr.
To test whether the presence of the pre-B-cell-specific factor
NF-'Tr (complex 1) correlates with the function of the vr
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FIG. 13. The IT site is conserved through the evolution of the IgH gene. Asterisks indicate identities.
enhancer element and to analyze the sequence requirements
for the binding of the different nuclear factors to the site,
we tested the specificity of binding in competition experi-
ments. The wild-type wr oligonucleotide as well as the mutant
'rr oligonucleotides Ml, M2, and M3 (Fig. 5) were used as
competitors in EMSA with the oligonucleotide-Sepharose
affinity-purified 200 mM KCl eluate from HAFIL cells and
the wild-type ir oligonucleotide as a probe (Fig. 12). The
wild-type oligonucleotide competed effectively with com-
plexes 1 (NF-'rr), 2, and 3 for binding (Fig. 12, lanes 2 to 4).
Equal amounts of mutant oligonucleotide Ml, which lacks
enhancer activity, still competed efficiently with complexes
2 and 3 but were unable to inhibit the binding of NF-ir (Fig.
12, lanes 5 to 7). Mutant oligonucleotide M2, with some
enhancer activity, competed slightly with NF-' but less
efficiently than the wild-type oligonucleotide (Fig. 12, lanes 8
to 10). Furthermore, mutant oligonucleotide M2 competed
very efficiently with complex 2 but very little with complex
3. Mutant oligonucleotide M3, with full enhancer activity,
competed effectively with NF-Tr, much less effectively with
complex 2, and not at all with complex 3 (Fig. 12, lanes 11 to
13).
These data demonstrate that mutations of the rr enhancer
element that abrogate its activity (Fig. 5) also eliminate the
binding of NF-'rr (Fig. 12) but have no effect or only a
marginal effect on the formation of complexes 2 and 3. On
the other hand, mutations that have no effect on r enhancer
activity have no effect on the binding of NF-'r but result in a
significant reduction in the formation of complexes 2 and 3.
These findings confirm that binding specificity and the pres-
ence of NF-ir strictly correlate with the activity of the
enhancer element in pre-B cells. On the basis of these
results, together with the DNase I footprinting results, we
can conclude that NF-'r binds to the 5' part of the 'rr site, to
the minimal sequence GCAGGAAGC. Complexes 2 and 3
appear to interact with the 3' part of the ir site but have very
little effect on the activity of the Tr enhancer element.
The enhancer element is conserved through the evolution
of the IgH gene. The importance of particular enhancer
elements for the transcriptional regulation of a gene is often
reflected in their conservation through evolution. When we
compared the DNA sequences of the murine, human, and rat
IgH enhancers (10, 15, 49), the only ones available, it was
evident that the Fr enhancer element is 100% conserved,
whereas other enhancer elements, including ,uB, ,uE2, and
,uE3, contain several nucleotide differences (Fig. 13). This
result suggests that the r enhancer element may be of crucial
importance for the proper regulation of IgH gene expression.
Regulatory regions of several B-cell-specific genes contain
sr-like DNA motifs. To examine the possibility that other
B-cell-specific genes are regulated through rr-like enhancers,
we analyzed the promoter and enhancer regions of a variety
of lymphoid cell-specific genes for the presence of Tr-like
DNA motifs. We observed rr-like DNA motifs in several
B-cell-specific genes, including v-preB (36), X5 (37), TdT
(61), and B29 (27) (Table 1), suggesting that NF-Fr may be
involved in the control of a whole set of B-cell-specific
genes. In addition, both the proximal and the distal promot-
ers of the T-cell-specific Ick gene (19, 67) contain a highly
homologous DNA motif that is 100% conserved. This fact
suggests that a T-cell-specific NF-rr-related protein may be
involved in T-cell-specific gene expression. Purified NF-'r
protein will enable us to determine whether these related
DNA motifs bind NF-Tr as well.
Their enhancer element shows a high degree of similarity to
binding sites for members of the ets transcription factor-
oncogene family. To determine whether previously described
transcription factors interact with the 'r enhancer element,
we compared the NF-'r-binding site with DNA motifs rec-
ognized by known transcription factors. We observed a
striking homology between the DNA-binding sites for mem-
bers of the ets gene family (48, 53, 64, 70) and that for NF-rr,
especially in the core GGAA motif (Table 2). In particular,
binding sites for PEA3 (71, 74) and Ets-1 and Ets-2 (23, 25,
29, 40, 53, 72) are remarkably similar to those for NF-rr.
Furthermore, the ,uB site of the IgH enhancer, which is
located downstream of iTr, contains a similar GGAA motif,
and we recently found that the Pu.1 transcription factor (35),
a member of the ets family, binds specifically to the ,uB site
and that its binding pattern correlates with the functional
activity of this site (1). We are now in the process of
evaluating the interaction of several members of the ets
TABLE 1. rr-related DNA motifs
Gene Species DNA sequence Location Expression Homology' Reference(s)
IgH (rr site) Mouse, human, and rat GGCAGGAAGCAGG Enhancer B cells 13 10, 15, 49
,-Related DNA motifs
v-preB Mouse GGGAGGAAGCACC Promoter Pre-B cells 10 36
X5 Mouse GGGAGGAAGCATA First intron Pre-B cells 10 37
TdT Mouse AGCAGGAAGTTGT Promoter Pre-B cells 9 61
B29 Mouse GGCAGGAAGGGGC Promoter B cells 10 27
Ick Mouse and human GGCAGGAAGCTTG Promoter 1 T cells 11 19, 67
Ick Mouse and human GGCAGGAAGCTTG Promoter 2 T cells 11 19, 67
a Number of homologous residues of a total of 13 residues.
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TABLE 2. Transcription factors with wr-related DNA-binding sites
Transcription factor DNA-binding sitea Geneb Reference(s)
NF-'rrl 5'-GGCAGGAAGCAGG-3' IgH 10, 15, 49
NF-,uB 5'-TATTGGGGAAGGG-3' IgH (mouse) 15
5'-TATTTAGGAAGCA-3' IgH (human) 49
ets related
ETS-1, ETS-2, ELK-1, ERG 5'-CAGGAAGTG-3' Polyomavirus 40, 59, 60, 71, 74
ETS-1 5'-CAGAGGATGTG-3' TCR-a 29
ETS-1, ETS-2 5'-AGAGCGGAAGCGCG-3' MSV 25
GABP-a 5'-CGGAAA-3' ICP4 69
SAP-1, ELK-1 5'-CACAGGATGTC-3' c-fos 12, 28
Pu.1 5'-AAAGAGGAACTTGG-3' MHCII I-AP 35
E74, ELK-1, SAP-1 5'-TAACCGGAAGTAAC-3' E74 53, 59
Elf-1 5'-AGGAGGAAAAA-3' IL-2 68
Elf-1 5'-GACAGGAACAG-3' HIV-2 38
ETS-1, ETS-2 5'-GGAGGAAAT-3' HTLV-I 23
a Boldfacing indicates consensus sequence.
b TCR-a, alpha T-cell receptor; MSV, murine sarcoma virus; MHCII I-AO, major histocompatibility class II antigen; IL-2, interleukin-2; HIV-2, human
immunodeficiency virus type 2; HTLV-I, human T-cell lymphotropic virus type I.
family with the Tr site. So far, antibodies against Pu.1 and
Ets-1 have failed to either prevent binding or to supershift
NEF-I in EMSA (data not shown). Furthermore, we recently
isolated a new member of the ets transcription factor family
from pre-B cells (47).
DISCUSSION
The IgH gene becomes rearranged during early stages of
B-cell differentiation and remains transcriptionally active
during all stages of B-cell differentiation (9, 63). We have
identified a new enhancer element, designated 7r, in the IgH
enhancer. We demonstrate that the ability to respond to the
'nr element occurs primarily during early stages of B-cell
development and is not evident in more mature B cells, even
those entering the stage of Ig K light-chain gene rearrange-
ment. Mutational analysis suggests that the 'r element is
crucial for IgH enhancer activity at the pre-B-cell stage but
is irrelevant for enhancer activity at the mature B-cell or
plasma-cell stage. The activity of the 'r enhancer element
correlates with the presence of an apparently pre-B-cell-
specific protein-DNA complex, NF-'rr, which might be re-
lated to the ets gene family (48, 54, 64). Because transcrip-
tion of the unrearranged IgH gene occurs prior to
rearrangement and appears to be essential for recombination
(9, 62, 63), the 'r element might be a critical activator of IgH
sterile transcription as well. A variety of other B-cell-specific
genes contain DNA motifs similar to 'r; thus, NF-7r might be
an important regulatory factor in the control of B-cell-
specific gene expression and B-cell differentiation.
The 'r site represents a novel pre-B-cell-specific regulatory
element in the IgH enhancer. Its similarity to binding sites
for ets-related transcription factors suggests that a member
of the ets gene family might interact with the 7r site. Indeed,
the IgH enhancer contains another ets-related enhancer
element, ,uB (42, 44, 52), with the typical 5'-GGAA-3'
sequence of ets-related binding sites (48, 53) occurring at its
center. We (1) have shown that pB binds a B-cell- or
macrophage-specific member of the ets family, Pu.1 (35).
Pu.1 appears, however, not to interact with 'Fr (1). There are
several other striking differences between the 'r site and the
p,B site, making it unlikely that the same factors interact with
both sites. Whereas ,B is active throughout B-cell develop-
ment (44, 52), 'r appears to act primarily at the pre-B-cell
stage. Furthermore, an isolated r site, but not an isolated ,uB
site, functions as an autonomous enhancer. In addition, gel
mobility shift assays for 'r and ,tB have revealed different
protein-DNA complexes and a distinct cell type distribution
(1). Therefore, we can assume that the IgH enhancer con-
tains at least two distinct ets-related enhancer elements with
strikingly different activities. This feature is very similar to
those of a whole set of T-cell-specific genes, including the
interleukin-2, alpha and beta T-cell receptor, CD2, and CD3
genes, all of which have at least two critical ets-related
enhancer elements (29, 68, 70). Several other B-cell-specific
genes, including the Ig K, TdT, and mb-i genes, apparently
also contain ets-related binding sites in their regulatory
regions (16, 26, 46, 58). We and others have shown else-
where that ,uB is important for the B-cell-specific activity of
the IgH enhancer (44, 52), and we now show the crucial role
of the 'rr site for the activity of the IgH enhancer at the
pre-B-cell stage. Therefore, it is likely that ets-related tran-
scription factors play similar crucial roles in B-cell-specific
gene regulation and potentially B-cell differentiation, as has
been proposed for T cells.
We do not know the identity of NF-'r yet. However, in an
attempt to isolate members of the ets gene family that are
expressed in pre-B cells, we recently cloned and character-
ized the gene for a novel ets-related transcription factor,
ERP (for Ets-related protein) (47). The expression of the
ERP factor in the B-cell lineage appears to be elevated at the
pre-B-cell stage and to decline upon B-cell maturation. We
are now in the process of determining whether ERP is able to
interact with the 'r site.
Several other ets-related enhancer elements, including
LyF-1 and BLyF, have been identified for other B-cell-
specific genes with binding sites similar to Fr (16, 46). On the
basis of the activities and expression patterns of LyF-1 and
BLyF, NF-i seems to be distinct from these factors.
We have noted the presence of 7r-related DNA sequences
in at least three pre-B-cell-specific genes, the TdT (61),
v-preB (36), and X5 (33) genes. We have no evidence as to
their function or whether they interact with NF-'r. Never-
theless, the presence of potential Ir sites in other genes
expressed at the pre-B-cell stage enhances the possibility
that NF-IT plays an important role in early B-cell gene
regulation and B-cell differentiation.
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